By Myles Starr
Treating patients with type 2 diabetes and chronic kidney disease with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide is effective in preventing the progression of kidney disease, as shown by clinical trial data recently published in The New England Journal of Medicine (2024 May 24. doi:10.1056/NEJMoa2403347). The results were so promising that Novo Nordisk, which funded the research, ended the study early.
“Semaglutide will be another game changer (in
JULY 3, 2024